News

UAB Epilepsy Center gains Level 4 recognition again

The Epilepsy Center at the University of Alabama at Birmingham has again been recognized as a Level 4 Epilepsy Center by the National Association of Epilepsy Centers.“Level 4 epilepsy centers have the professional expertise and facilities to provide the highest-level medical and surgical evaluation and treatment for patients with complex epilepsy,” according to David Labiner, M.D., president of NAEC.

Centers designating Level 3 or Level 4 status attest that their epilepsy center meets the criteria stated in the NAEC Guidelines for Essential Services, Personnel, and Facilities in Specialized Epilepsy Centers in the United States.

UAB’s center, housed in the Department of Neurology under the direction of Jerzy Szaflarski, M.D., Ph.D., features six neurologists specializing in epilepsy, along with specialists in neurosurgery, pharmacology and neuropsychology. The center is also home to the new UAB Cannabidiol Program, created by the passage of Carly’s Law by the Alabama legislature.

Bob Shephard

Dr. David S. Geldmacher named the Patsy W. and Chales A. Collat Endowed Professorship in Neuroscience

Endowed professorship in neuroscience established – The University of Alabama System Board of Trustees approved the establishment of the Patsy W. and Charles A. Collat Endowed Professorship in Neuroscience in the UAB Department of Neurology and named David S. Geldmacher, M.D., its inaugural holder during its meeting April 4. The position will promote research and education in neuroscience with a focus in memory disorders. The Collats have given numerous gifts to UAB, and to UAB’s neuroscience program in particular, including making possible the Charles A. and Patsy W. Collat Endowed Chair in Neurosurgery. Geldmacher joined the UAB faculty in 2011 and directs the Division of Memory Disorders and Behavioral Neurology.

Viral therapy proven safe, shows promise against deadliest brain tumors



A genetically engineered herpes simplex viral therapy is safe when used with radiation to treat malignant gliomas, one of the most deadly forms of brain cancer, UAB researchers say.The virus, G207, shown to be safe as a sole therapy in two previous UAB studies, also is safe when combined with low doses of radiation, according to results published in "Molecular Therapy."

                                                                                 james markert web


Some patients also showed evidence of tumor reduction, and survival rates were increased for others.

“This was a Phase I study designed foremost to see whether the therapy was safe,” said James M. Markert, M.D., Ph.D., professor and chair of UAB's Department of Neurosurgery and the study’s first author.

“While this study, with a limited number of patients and no controls, prevents any conclusions about the efficacy of this treatment, the decrease in tumor size seen on MRI’s in some patients, and an increase in survival in some patients without other proven treatment options, is highly encouraging,” Markert said.

The virus works by infecting tumor cells and replicating until it overwhelms the cell’s machinery and causes the cell to rupture and die, releasing new viral particles. The virus has been genetically modified so that it can reproduce only in tumor cells, which lack the stronger antiviral defense mechanisms of healthy brain cells. After destroying a tumor cell, the virus moves on, looking for new tumor cells to infect.

“While this study, with a limited number of patients and no controls, prevents any conclusions about the efficacy of this treatment, the decrease in tumor size seen on MRI’s in some patients, and an increase in survival in some patients without other proven treatment options, is highly encouraging.”
“Additional studies with modified viruses such as G207 in the treatment of human glioma are certainly warranted from the results of this trial,” Markert said.

Gliomas account for about a third of brain tumors, and survival rates are poor; only about half of the 10,000 Americans diagnosed with malignant glioma survive the first year, and only about one-quarter survive for two years.

UAB is preparing another study with a new modified herpes simplex virus, M032, which preliminary studies indicate could be even more effective. It includes a genetically engineered protein called IL12, which the researchers believe will induce a stronger immune response and will contribute to increased anti-angiogenesis, the process of shutting off the blood supply to tumor cells, denying oxygen and essential nutrients.



         

Published in Research & Scholarship

Brain Bodyguard

0314 geldmacher2

David Geldmacher Makes Moves Against Alzheimer's

By Robin Sutton Anders and Eleanor Spicer Rice
Alzheimer’s disease affects millions of Americans and is the nation’s sixth leading cause of death. Alzheimer’s is marked by the accelerating death of brain cells, which means early detection is critical, says David Geldmacher, M.D., director of the UAB Division of Memory Disorders and Behavioral Neurology and Charles and Patsy Collat Professor of Neurology. Geldmacher, an expert on Alzheimer’s diagnosis and management, shares his latest research and reveals some common myths about the disease.

UAB Magazine:
Why is your research focused on the earliest stages of Alzheimer’s disease?
Geldmacher: We haven’t discovered a way to effectively make brain cells grow back. Once they’re lost, they’re gone forever. We need to intervene earlier, at the point when brain damage can be minimized. With modern technology, we can recognize biological changes in the brain before disabling levels of memory loss occur.

UAB Magazine:
What potential therapies are you testing in your lab?

Geldmacher:
We know one of the crucial features of Alzheimer’s is the abnormal accumulation of a normal protein called the amyloid peptide. Many of our treatments target that peptide. We look at medications that can prevent amyloid from forming, or that try to remove it once it has formed. We also look at medications that try to lessen amyloid’s toxic effects on brain cells. And we are testing medications that can potentially help affected brain cells work better or resist amyloid’s toxic effects.

UAB Magazine:
One of your goals is to boost the amount of clinical research in Alzheimer’s. Why is this so important?

Geldmacher:
Without a placebo-controlled trial, no new medicine can come to market. This is the bridge from the research labs to the doctor’s office. We need to know the drugs are safe and that they work in people—not just animals. The only way to do that is to test them in people who have volunteered.

UAB Magazine:
You are also focused on integrated care for patients with Alzheimer’s. What does that mean?

Geldmacher:
The Alzheimer’s disease process leads to less and less independence, and eventually people lose the ability to be mobile. They end up in their chairs or beds because their brains can’t follow through with purposeful mobility. Complications like blood clots in legs can end up causing death. Another common difficulty is people lose the know-how to eat and hydrate themselves.

We frequently find that the care a patient receives gets fragmented across physicians. Neurologists and psychiatrists prescribe medications that affect the patient while a primary care physician is helping to manage their blood pressure or diabetes. It’s difficult to keep patients and doctors in sync even though they’re all dealing with elements of the same illness. Communication is important.

Through the UAB Memory Disorders Clinic, members of our nursing staff can provide support and information. And we have a referral network within the UAB system with neurologists, geriatricians, speech therapists, psychologists, and other relevant specialists who can communicate with each other quickly and effectively. One of our goals is to strengthen the network of health-care providers who can work together to meet patients’ needs. An integrated care team that includes nursing, psychology, social work, and rehabilitation services like speech and occupational therapy can help people with Alzheimer’s disease maintain their highest levels of independence and daily function. I think that these services help maintain the highest possible quality of life for people with Alzheimer’s.

UAB Magazine:
Do you find that general practitioners have any misconceptions about Alzheimer’s?

Geldmacher:
There is still a common perception that there isn’t much we can do for people with Alzheimer’s. But we’re learning there are things we can do to help people maintain their well being through physical exercise, mental stimulation, and a healthy diet. Those three things may help to prevent the disease or slow it down. [See Geldmacher’s five tips on lifestyle choices that can affect Alzheimer’s.]
The other misconception is that disabling levels of memory loss are part of the aging process. That’s clearly not true. There’s growing evidence that treatment with our existing medications, such as cholinesterase inhibitors, has a meaningful long-term impact.

UAB Magazine:
What do you wish the public knew about Alzheimer’s?

Geldmacher:
It’s a biological disease, not a mental illness. It’s not a weakness or the fault of the person who developed it. For the vast majority of cases, we still don’t know what triggers the disease. It appears that there isn’t just one cause, but a series of interactions between genetics, lifestyle, small strokes, and concussions. When people have a certain combination of factors, which might differ from one person to the next,the disease shows up.